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ABSTRACT
The February 2015 issue of ckj started a new era with renewed efforts to be useful to the training and practicing
nephrologists and a new focus on Clinical and Translational Nephrology. Four years later, it has become a truly global
journal with contributors and readers from all over the world. The increase in quality of the published material has resulted
in a nearly exponential growth of citations. Since 2016, ckj is listed in the new Emerging Sources Citation Index (ESCI)
database from Clarivate Analytics and from January 2019 it will be listed in the full Science Citation Index. ckj will therefore
receive its first official impact factor based upon 2018 citation to 2016 and 2017 articles. While no official impact factor was
awarded for 2017, the estimated impact factors calculated from data available in Clarivate’s Web of Science database rose to
2.987 in 2017, which would correspond to an estimated journal impact factor percentile of 72.4% in the Urology and
Nephrology field.
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NDT Plus was launched in 2008. The Editor-in-Chief, Norbert
Lameire, aimed at providing an educational and training resource
for practicing nephrologists [1]. In 2012, NDT Plus evolved into the
Clinical Kidney Journal (ckj) and flourished as an educational tool
under the editorship of Alain Meyrier [2, 3]. In 2015, Alberto Ortiz
was elected Editor-in-Chief for a first term that just ended. A sub-
heading was added to ckj emphasizing the new focus: Clinical
and Translational Nephrology [4]. The vision was further ex-
panded in a series of articles on Translational Nephrology [5, 6].
The journal became open access, online-only, and fully search-
able and accessible through PubMed. Submission and publishing
fees have been waived ever since. The types of manuscripts were
streamlined to editorial comments, ckj reviews, original articles
and exceptional case reports.
Over the past 4 years, the number of published items de-
creased when compared with the younger ckj (Figure 1A). This
was a consequence of a higher quality threshold for publication.
Thus, the number of submissions was 449 in 2015 and is
expected to hover around 480 in 2018. However, the acceptance
rate decreased from 40% in 2013 to 36% in 2015 and 26% in 2018.
The types of manuscripts published shifted to an increase of
high-quality ckj reviews and original manuscripts. These
changes were well received by the nephrological community
and the number of citations per year exponentially increased
(Figure 1B). In 2016, ckj was accepted for indexing in the new
Emerging Sources Citation Index (ESCI) database from Clarivate
Analytics (previously Thomson Reuters). From January 2019 it
will be listed in the full Science Citation Index. ckj will therefore
receive its first official impact factor based upon 2018 citation to
2016 and 2017 articles. While no official impact factor was
awarded for 2017, the estimated impact factor calculated from
data available in Clarivate’s Web of Science database rose to
2.987 in 2017 (Figure 2A). In this regard, it is estimated that ckj
is approaching the first quartile (Q1, 25% top journals as
assessed by impact factor) in the Urology and Nephrology field
(Figure 2B). In the 2017 impact factor database, released in June
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2018, there were 10 Urology and 9 Nephrology journals in Q1. Of
the latter, only five published original manuscripts.
ckj has become a global reference for practicing nephrolo-
gists. The main geographical origin of submissions is the USA
(22–25% across 2015–18). On the other side of the coin, the top
five user countries were, in this order, USA, Great Britain, India,
Canada and Australia. However, there were users from a total of
210 countries in 2018, making it a truly global journal (Figure 3).
The most cited manuscripts in this new era are listed in
Tables 1–3. Over the past 4 years, the most cited items were
ERA-EDTA Registry reports and systematic reviews (Table 1) [7–
18]. As expected, older items have gathered more citations.
Thus, we provide one table focusing on 2017 (Table 2) and one
for 2018 (Table 3) [19–45]. Among the most cited topics, we find
systematic reviews and meta-analysis on exercise, vitamins K
and D, and assessment of renal function and injury, including
the use of a urine peptidomics-based marker of kidney injury
recently refined to beat glomerular filtration rate and urinary
albumin:creatinine ratio for prediction of chronic kidney dis-
ease (CKD) progression when the estimated glomerular filtra-
tion rate is still not diagnostic of CKD [46]. Other topics that
drew the attention of authors were onconephrology, the interre-
lationship of the gut microbiota and kidney disease, low-protein
diets, residual renal function, eculizumab, sustainability of re-
nal replacement therapy, socioeconomic and psychosocial fac-
tors and gender impact on CKD, CKD hotspots, management of
hyperphosphataemia, hyperkalaemia, hyperuricaemia and
acute kidney injury (AKI). Many topics were shared with the 100
most cited papers in nephrology, presented in this issue of ckj,
suggesting overall clinical interest for the nephrological com-
munity. Shared topics include renal function assessment, phar-
macology, dialysis/transplantation, AKI and CKD [47].
In contrast, the top downloaded articles were very practical in
approach and included the 2017 update on pain management in
patients with CKD [48] and a manuscript on palliative care for
patients with end-stage renal disease [49], both published in 2017.
In 2018, the top downloaded articles dealt with high-dose vitamin
K for calciphylaxis [50], therapy of childhood C3 glomerulopathy
[51] and hyponatraemia in kidney transplant patients [52].
A different vision of the impact of ckj is provided by the
Altmetrics score. In 2018, the three top manuscripts dealt with
the ‘ExTra CKD’ trial of supervised exercise in CKD [53], living
kidney donor use of marijuana [54] and the EMPA-KIDNEY study
of sodium/glucose cotransporter 2 (SGLT2) inhibitors in CKD [55].
As part of our focus on education, ckj has started a collabora-
tion with GlomCon and the ERA-EDTA Young Nephrologists’
Platform in 2018. Up to now, two ckj manuscripts have been dis-
cussed in the Journal Club webinar with active participation of the
Editor-in-Chief and in some cases of the authors [56, 57]. For 2019,
the manuscript ‘Risk factors associated with post-kidney
transplant malignancies: an article from the Cancer-Kidney
International Network’ by Sprangers et al. [58] is scheduled to be
discussed on 7 May 2019.
A
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FIGURE 1: ckj over the years. (A) Number of published items. (B) Number of cita-
tions per year according to Web of Science, accessed 18 December 2018.
A
B
FIGURE 2: ckj and estimated impact factor. (A) Estimated impact factors calcu-
lated from data available in Clarivate’s Web of Science database. They are not
official impact factors. (B) Estimated journal impact factor (JIF) percentile in the
Urology and Nephrology field.
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[9%]
[8%][4%]
[3%]
[37%]
FIGURE 3: Country of origin of ckj online users in 2018. Numbers represent per-
centage of total individual users.
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Hopefully, we will relay to the next Editor-in-Chief, to be
elected in 2021, an internationally renowned journal that
continues to be a required and useful read for nephrologists in-
training and practicing nephrologists.
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